

Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

Andrea Moreno-Arciniegas¹, Alberto García², Malte Kelm³, Francesco D'Amore⁴, María Gomes da Silva⁵, Javier Sánchez-González⁶, Pedro L. Sánchez^{7,8}, Teresa López-Fernández⁹, Raul Córdoba², Riccardo Asteggiano¹⁰, Vincent Camus¹¹, Jouke Smink¹², Antonio Ferreira¹³, Marie J. Kersten¹⁴, Natacha Bolaños¹⁵, Noemi Escalera^{1,8}, Elsa Pacella¹⁶, Sandra Gómez-Talavera^{1,2,8}, Antonio Quesada¹, Xavier Rosselló^{1,8,17}, and Borja Ibanez^{1,2,8*}, RESILIENCE Trial Investigators[†]

¹Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; ²IIS-Fundación Jiménez Díaz, Madrid, Spain; ³Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany; ⁴Aarhus University Hospital, Aarhus, Denmark; ⁵Hematology, Instituto Português de Oncologia de Lisboa (IPO Lisboa), Lisbon, Portugal; ⁶Philips Healthcare Iberia, Madrid, Spain; ⁷Hospital Universitario de Salamanca, Salamanca, Spain; ⁸CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; ⁹Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain; ¹⁰Faculty of Medicine, Insubria University, Varese, and Laboratorio Analisi e Ricerca Clinica, Turin, Italy; ¹¹Centre Henri Becquerel, Department of Hematology and INSERM U1245, Rouen, France; ¹²Department of MR R&D—Clinical Science, Philips, Best, The Netherlands; ¹³Hospital da Luz, Lisbon, Portugal; ¹⁴Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ¹⁵Lymphoma Coalition Europe, Madrid, Spain; ¹⁶European Society of Cardiology, Nice, France; and ¹⁷Hospital Universitari Son Espases-IDISBA, Universitat Illes Balears, Palma de Mallorca, Spain

Received 2 April 2024; revised 1 July 2024; accepted 9 July 2024

Aims

There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC.

Methods

REmote iSchemic condltioning in Lymphoma Patlents REceiving ANthraCyclinEs (RESILIENCE) is a multinational, prospective, phase II, double-blind, sham-controlled, randomized clinical trial that evaluates the efficacy and safety of RIC in lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥ 5 chemotherapy cycles including anthracyclines and with ≥ 1 AC-associated risk factors will be randomized to weekly RIC or sham throughout the chemotherapy period. Patients will undergo three multiparametric cardiac magnetic resonance (CMR) studies, at baseline, after the third cycle (intermediate CMR), and 2 months after the end of chemotherapy. Thereafter, patients will be followed up for clinical events over an anticipated median of ≥ 24 months. The primary endpoint is the absolute change from baseline in CMR-based left ventricular ejection fraction (LVEF). The main secondary outcome is the

*Corresponding author: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and IIS-Fundación Jiménez Díaz University Hospital, c/ Melchor Fernandez Almagro 3, 28029 Madrid, Spain. Email: bibanez@cnic.es


[†]Full list of investigators/collaborators is provided in online supplementary Appendix S1.

incidence of AC events, defined as (1) a drop in CMR-based LVEF of ≥ 10 absolute points, or (2) a drop in CMR-based LVEF of ≥ 5 and < 10 absolute points to a value $< 50\%$. Intermediate CMR will test the ability of T2 mapping to predict AC versus classical markers (left ventricular strain and cardiac injury biomarkers). A novel CMR sequence allowing ultrafast cine acquisition will be validated in this vulnerable population.

Conclusions

The RESILIENCE trial will test RIC (a novel non-invasive intervention to prevent AC) in a cohort of high-risk patients. The trial will also test candidate markers for their capacity to predict AC and will validate a novel CMR sequence reducing acquisition time in a vulnerable population.

Graphical Abstract



RESILIENCE clinical trial overview. BNP, B-type natriuretic peptide; ChT, chemotherapy; CMR, cardiac magnetic resonance; Q, questionnaire; RIC, remote ischaemic conditioning.

Keywords

Cardiotoxicity • Anthracyclines • Cardio-oncology • Cardioprotection • Heart failure • Ischaemic conditioning • Magnetic resonance imaging • Strain • Biomarkers • Randomized clinical trial

Introduction

Anthracyclines, alone or in combination, remain the first-line therapy for many cancers, including various forms of lymphoma, breast cancer, leukaemia, melanoma, and uterine and gastric cancers.¹ Every year, anthracyclines are administered to > 3 million European citizens to treat a first cancer. The curative potential of anthracycline therapy is determined by appropriate dosing.² Anthracyclines have a well-known cardiotoxic effect that can result in irreversible injury to the myocardium, leading to chronic heart failure (HF).³ While the major determinant of anthracycline cardiotoxicity (AC) is cumulative dose, the risk of this adverse effect is increased by older age and the presence of other comorbidities, including ischaemic cardiomyopathy, valvular heart disease, and hypertension.⁴ An estimated $> 5\%$ of cancer survivors live with chronic HF secondary to AC.⁵ There is a pressing need to identify treatments able to prevent AC.⁶

Among several cardioprotective therapies that have been tested experimentally, a promising candidate for translation to the clinic is remote ischaemic conditioning (RIC). In RIC, brief episodes

of ischaemia followed by reperfusion in one body part (usually a limb) render remote tissues and organs resistant to injury.⁷ In pigs, which have a human-like cardiovascular anatomy, RIC has been shown to prevent AC through a mechanism involving mitochondrial protection.⁸ RIC is a safe and effective, non-invasive, feasible, and inexpensive intervention that has mainly been tested in the context of myocardial infarction and stroke.^{9,10}

Early identification of AC while patients are on-treatment is essential so that cardiovascular follow-up can be intensified, general HF therapy initiated, and cancer treatment regimens eventually modified. The currently recommended criterion for early AC diagnosis is echocardiographic global longitudinal strain (GLS).⁴ However, GLS disturbances are not detected until after the appearance structural damage to the myocardium. An ideal early AC marker would be altered before the appearance of any structural or functional abnormality. In a large animal (pig) model, the earliest identification of AC was achieved with cardiac magnetic resonance (CMR) T2 mapping.¹¹ While T2 prolongation has yet to be formally validated as an AC marker in humans, pilot clinical data suggest that

T2 mapping is altered early in cancer patients,¹² suggesting that CMR could be an ideal risk-stratification tool for cancer patients on anthracyclines. However, CMR acquisition times are normally between 45 and 60 min.¹³ Cancer patients are a vulnerable population, and long scan times can cause particular discomfort. A novel CMR methodology was recently developed that massively reduces scan times to less than 1 min,¹⁴ but this new method has not previously been tested in a vulnerable patient population.

RESILIENCE (REmote iSchemic conditioning in Lymphoma Patlents REceiving ANthraCyclinEs) is a European Commission-funded project aimed at reducing the prevalence of anthracycline chemotherapy-related HF in cancer survivors. The central activity is a randomized clinical trial evaluating the efficacy and safety of RIC in lymphoma patients receiving anthracyclines and at risk of cardiotoxicity (RESILIENCE trial, NCT05223413). The project additionally includes prospective controlled studies to validate T2 mapping as an early marker of AC and ultrafast CMR to achieve massively reduced scan times.

Methods

Study design

RESILIENCE is a multinational, phase II, prospective, double-blind (sham-controlled) randomized clinical trial evaluating the efficacy and safety of RIC in lymphoma patients receiving anthracyclines and at risk of cardiotoxicity. The sponsor is the Centro Nacional de Investigaciones Cardiovasculares (CNIC), a publicly funded non-profit research institute in Madrid, Spain. The study is funded by the European Commission through the Horizon 2020 Framework Programme, call H2020-SC1-BHC-2018-2020 'Better Health and care, economic growth and sustainable health systems'.

The enrolled study population consists of patients with a first lymphoma diagnosis, scheduled to undergo ≥ 5 chemotherapy cycles including anthracyclines, and having a risk factor for AC ≥ 1 . Eligible patients undergo a baseline CMR study and will be randomized to RIC or a sham procedure, with stratification by gender, recruitment centre, and baseline left ventricular ejection fraction (LVEF) (41–50%, 51–60%, >60%). Patients undergo three CMR studies: before starting anthracycline-based chemotherapy (baseline), between the third and fourth chemotherapy cycles, and 9 weeks after the final chemotherapy cycle. On the same day as the CMR studies, blood samples are obtained for the determination of cardiac injury biomarkers (high-sensitivity troponin [hsTn] and B-type natriuretic peptide [BNP]). Patients are monitored for clinical events at 6, 12, 18, 30, and 42 months after enrolment. When the last patient to be enrolled undergoes the final CMR, clinical follow-up will be closed for all patients, and patients who have not reached the 42-month follow-up will attend a final visit at that time. The anticipated median clinical follow-up is therefore 24 months. The trial outline is depicted in the *Graphical Abstract*.

Study hypothesis

The main hypothesis of the RESILIENCE trial is that RIC will reduce the incidence of AC. A second hypothesis is that T2 relaxation time in the intermediate CMR exam will predict AC more accurately than other markers (left ventricular [LV] strain or circulating biomarkers). The third hypothesis is that in this vulnerable population of cancer patients, the ultrafast ESSOS three-dimensional (3D) single breath-hold CMR

cine sequence will yield similar results to the standard two-dimensional (2D) sequence.

Study population: inclusion/exclusion criteria

Eligible patients are those with a first diagnosis of lymphoma (non-Hodgkin or Hodgkin) scheduled to undergo ≥ 5 chemotherapy cycles containing anthracyclines and having at least one risk factor for AC. Patients fulfilling all inclusion and no exclusion criteria on screening undergo baseline CMR. When CMR-based LVEF is confirmed to be above 40%, patients are randomized 1:1 to RIC versus simulated RIC (sham). Inclusion and exclusion criteria are listed in *Table 1*.

Randomization

Baseline CMR data are transferred to the core lab, where LVEF is quantified within two working days. CMR-based LVEF qualification includes its categorization as 41–50%, 51–60%, and >60% for stratification purposes. Further CMR analyses are performed later (see CMR section). Local investigators (blinded to core lab LVEF quantification) are then informed that the patient can be randomized and access the web-based electronic case report form (eCRF)-management application REDCap and click for randomization. Randomization is stratified by LVEF (41–50%, 51–60%, and >60%), sex (male/female), and enrolling centre. The system assigns a randomization number that serves as a unique device identifier. The assigned device corresponds to RIC or the sham procedure (double-blind allocation). See RIC device section for additional information.

Remote ischaemic conditioning

Sham devices

Remote ischaemic conditioning has been tested in several large randomized clinical trials of several thousands of patients experiencing a myocardial infarction¹⁰ or stroke¹⁵ or undergoing cardiac surgery,^{16,17} proving to be extremely safe. For this trial, devices were purchased from Seagull Aps (one device per enrolled patient). Seagull Aps RIC devices were used in a recent trial enrolling 1500 stroke patients, with no reported serious device-related safety concerns.¹⁵

The device has two independent components: a portable blood pressure monitor, and a CE-marked blood pressure cuff. A device of the type to be used in the RESILIENCE trial is shown in *Figure 1*. The pressure-monitor software has been modified to automatically apply a complete RIC or sham session (four cycles of 5 min inflation and 5 min deflation) instead of a regular blood pressure measurement. The RIC and sham procedures are distinguished by the cuff inflation pressure used: above systolic blood pressure in the RIC procedure, to induce arm ischaemia; or residual pressure (≈ 20 mmHg) in the sham procedure. When switched on, the device automatically takes a regular blood pressure reading and then initiates the RIC or sham procedure. The device automatically shuts down after completing the fourth RIC/sham cycle.

The device records full information related to each use (including cycles, inflation pressures, etc.), and the aggregated information for multiple intervention days is later downloaded by the research team during the next site visit. In this way, device operation will allow the assessment of adherence to intervention.

Sham intervention protocol

Upon enrolment, patients receive training in how to operate the RIC/sham device. The first RIC/sham intervention is performed and

Table 1 Inclusion/exclusion criteria

Inclusion criteria	Exclusion criteria
1. Signed informed consent form 2. ≥ 18 years old 3. First NHL or HL diagnosis 4. Scheduled to undergo ≥ 5 chemotherapy cycles including any anthracycline 5. Pre-chemotherapy LVEF $>40\%$ 6. Sinus rhythm on screening ECG 7. Presence of ≥ 1 of the following risk factors for AC: - Previous coronary artery disease^a - LVEF 41–54% on screening echocardiography - Age ≥ 65 years old - Previous diagnosis of arterial hypertension - Chronic kidney disease (eGFR <60 ml/min/1.73 m²) - Current smoker (≥ 20 packs of cigarettes per year) - Former smoker (≥ 20 packs of cigarettes per year) who quit ≤ 10 years before - BMI ≥ 30 kg/m² - LV thickness ≥ 12 mm on echocardiography screening - High alcohol intake (≥ 21 standard drinks per week) - Previous diagnosis of diabetes - Previous non-anthracycline-based chemotherapy	1. Previous treatment with anthracyclines 2. Previous clinical diagnosis of heart failure 3. Permanent atrial fibrillation 4. Severe valvular or sub-valvular heart disease 5. Severe peripheral arterial disease in the upper extremities or arteriovenous shunt 6. Diabetic neuropathy 7. Diabetes actively treated with sulfonylureas 8. Contraindication for contrast-enhanced CMR^b 9. Platelet count $<50\,000/\mu\text{l}$ in any blood test in the previous 3 months 10. Participation in other clinical trials 11. Inability to consent or undergo study follow-up

AC, anthracycline cardiotoxicity; BMI, body mass index; CMR, cardiac magnetic resonance; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HL, Hodgkin lymphoma; LV, left ventricular; LVEF, left ventricular ejection fraction, NHL, non-Hodgkin lymphoma.

^aAny of the following: (i) previous coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting); (ii) medical history of significant non-revascularized coronary stenosis; (iii) previous acute coronary syndrome/acute myocardial infarction with LVEF $>40\%$.

^bAny of the following: (i) severe claustrophobia; (ii) any device which is known to threaten or pose a hazard in any magnetic resonance environment; (iii) presence of a pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization device.



Figure 1 Remote ischaemic conditioning device. The remote ischaemic conditioning device is very similar to a blood pressure monitor, but with modification to maintain a target pressure of 200 mmHg for 5 min, causing ischaemia in the upper limb. In remote ischaemic conditioning, brief, reversible episodes of ischaemia followed by reperfusion in one body part (usually an arm) render remote tissues and organs resistant to injury.

completed under the supervision of study nurses before the initiation of chemotherapy, on the same day as the first anthracycline injection. Patients then take the device home and perform the intervention themselves once a week throughout the chemotherapy period. In addition to the weekly at-home RIC/sham intervention, patients undergo daily RIC/sham procedures during each chemotherapy cycle, with the intervention completed before commencing anthracycline infusion. The final RIC/sham intervention is scheduled for 1 week after the final chemotherapy cycle.

Study endpoints

Primary endpoint:

- Absolute change in LVEF (between baseline and either follow-up CMR, whichever shows the lower LVEF).

Key secondary endpoints:

- Rate of AC events (based on the drop in LVEF between baseline and either of follow-up CMR, whichever shows the lower LVEF). An AC event is defined as either of the following: (i) a drop in LVEF ≥ 10 absolute points regardless of the absolute value of the follow-up LVEF; (ii) a drop in LVEF ≥ 5 and <10 absolute points to a follow-up LVEF $<50\%$.
- Rate of atrial fibrillation.
- Rate of hospital admission for sustained ventricular tachycardia or ventricular fibrillation or resuscitated cardiac arrest.
- Time to all-cause death.
- Time to hospitalization for HF.
- Tumor regression.
- Change in quality of life (QoL, scored by questionnaire) between baseline and two time points, coinciding with the intermediate CMR (after the third chemotherapy cycle) and the final CMR (9 weeks after the final chemotherapy cycle).

Exploratory endpoints:

- Sex differences in the incidence of the primary endpoint.
- Sex differences in the incidence of AC events.
- Difference between study groups (RIC vs. sham) in the change in myocardial perfusion between CMR scans.
- Difference between study groups in the change in T1 and T2 relaxation times between CMR scans.
- Differences between study groups in changes in LV strain derived from tagging, feature tracking, and fast-SENC sequences between CMR scans
- Differences between study groups in late gadolinium enhancement (LGE) area and extracellular volume fraction in the final CMR.
- Differences between study groups in the change in end-diastolic volume between CMR scans.




Figure 2 RESILIENCE cardiac magnetic resonance (CMR) imaging protocols. The CMR protocols include steady state free precession (SSFP) cine imaging in long-axis orientation (2-, 3-, and 4-chamber [Ch]) and short-axis orientation (SA). All patients undergo the basic protocol, and a predicted >50% of patients will additionally undergo the advanced protocol. Each patient will undergo the same procedure (basic or basic + advanced) in all three CMR studies (baseline, intermediate, and final 9 weeks after last chemotherapy cycle). The basic CMR protocol includes assessment of two-dimensional cardiac anatomy and function, left ventricular strain tagging, T2 mapping, pre- and post-gadolinium T1 mapping, and T1W late gadolinium enhancement (LGE). The advanced CMR protocol includes the following sequences: fast-strain encoded (fast-SENC), quantitative perfusion imaging, ultrafast (single breath-hold) ESSOS (enhanced sensitivity encoding [SENSE] by static outer volume subtraction) three-dimensional (3D) cine sequence, and ultrafast 3D isotropic LGE.

- Difference between study groups in the change in LV sphericity index between CMR scans.
- Difference between study groups in the change in CMR-measured LV diastolic function between CMR scans.

Quality of life evaluation

Quality of life is assessed using three widely used questionnaires for this vulnerable population: the Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO), the EuroQoL EQ-5D Questionnaire, and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12).

In addition to these three validated QoL questionnaires, an 11-item ad hoc questionnaire to evaluate discomfort produced by the intervention is completed 90 min after each RIC/sham session. The first nine questions on this ad hoc questionnaire ask about the perception of any of the following signs and symptoms affecting the cuffed arm: pain (scored from 0 to 10); tingling, such as pins and needles; numbness; tightness; redness or bluish marbling; skin marking where the cuff was placed; swelling of the fingers or hand; loss of sensitivity in the arm, forearm, or fingers; and the presence of haematoma. Questions 2 through 8 have three response options: *No/A little/A lot*, whereas question 9 has four: *None/Petechiae (tiny purple, red, or brown spots on the skin)/Mild haematoma/Large haematoma*. Item 10 asks patients to describe (in free text) any other sign or symptom not found on the list, thus providing space for the reporting of less likely symptoms such as difficulty in moving the arm, hand, or wrist. The final item asks if the

device functions correctly and has four response options: *Yes/It does not work/ It does not perform or complete the four cycles/It does not inflate and/or deflate*.


Cardiac magnetic resonance acquisition protocol and analysis

Overt AC, the main outcome measure in RESILIENCE, will be identified with CMR. The CMR scans will also be used to validate two novel CMR methodologies: T2 mapping for the early diagnosis of cardiotoxicity, and the ESSOS sequence for massively reduced scan time.

The main parameter used for the diagnosis of overt AC is LVEF deterioration.¹⁸ CMR is the most accurate technique for determining LVEF, showing the least variability of all imaging modalities. Furthermore, CMR is the gold-standard methodology for cardiac anatomical and functional evaluations. In line with international consensus documents,¹³ the primary and most key secondary outcome measures in RESILIENCE are CMR based.

Imaging protocol

All patients will undergo a comprehensive basic protocol that includes 2D assessment of cardiac anatomy and function, LV strain tagging, T2 mapping, pre- and post-gadolinium T1 mapping, and T1w LGE. In addition, >60% of patients (those enrolled at centres equipped with specific Philips magnets) will undergo an additional advanced protocol comprising ultrafast (single breath-hold) ESSOS 3D cine sequence,¹⁴ ultrafast



(single breath-hold) 3D isotropic LGE,¹⁴ quantitative perfusion imaging,¹⁹ and fast-SENC.²⁰ The CMR protocol is summarized in Figure 2.

Cardiac magnetic resonance analysis

All scan data are transferred to the core imaging laboratory at the CNIC for blinded analysis. All analyses are performed by technicians specialized in cardiac imaging and reviewed by two cardiologists specialized in advanced cardiac imaging. Data from analyses are uploaded to the corresponding eCRF. Within two working days of the baseline CMR scan, baseline LVEF is analysed and uploaded to the eCRF for stratified randomization. All other analyses are performed later. Studies are analysed in a random order.

Cardiac anatomy, function, T1/T2 mapping, LGE, quantitative perfusion and ESSOS are analysed with the Philips Intellispace Portal application. LV strain determined by tagging and feature tracking is analysed with the commercially available Segment application (<http://segment.heiberg.se>), and LV strain determined by fast-SENC is analysed with the Myostrain application, providing global and segmental longitudinal and circumferential strain.

Before opening for recruitment, all enrolling centres underwent a quality control screen consisting of a complete CMR study obtained with precise adherence to the trial protocol. These tests have been

reviewed to ensure sufficient quality for satisfactory quantification of all study parameters.

Follow-up and study outcomes

In addition to follow-up sessions coinciding with attendance for CMR scans and chemotherapy, a further four follow-up sessions are scheduled, at 12, 18, 30, and 42 months after recruitment. The first and third of these are telephone sessions, whereas the second and final sessions are in-person. When the last enrolled patient reaches the final CMR, this will mark the end of the study follow-up period, and all actively participating patients will be scheduled to attend the hospital for the final follow-up session, regardless of when the previous visit was. The anticipated median follow-up is thus 24 months (minimum 6 months, maximum 42 months). The study activities are summarized in Figure 3.

RESILIENCE has an expected duration of 5 years from the trial launch in 2021. A minimum follow-up of all patients will be performed 9 weeks after the last chemotherapy cycle (approximately 6 months after recruitment).

Sample size calculation

At 9 weeks after the final chemotherapy cycle (coinciding with the final CMR), we anticipate an absolute change in LVEF (primary endpoint)

of five points in the sham group. A total of 506 patients (253 per group) with baseline and follow-up CMR will be needed to detect a 40% relative reduction in the intervention group (a 3% drop in LVEF in absolute terms), with a common standard deviation of 8.8 points, 80% power, and two-sided $\alpha = 0.05$. Based on a predicted maximum withdrawal from follow-up CMR of 17% (102 patients), the target sample size is set at 608 patients (304 per group).

As of 31 January 2024, patient enrolment had begun at all 18 centres, located in six countries (online supplementary Appendix S1), and 148 patients had been enrolled. Up-to-date real time information can be found in the newsletters posted on the project webpage (<https://resilience-h2020.com/>).

RESILIENCE consortium, participating centres

The RESILIENCE project receives funding from the European Union Horizon 2020 Research and Innovation Programme under grant agreement No. 945118; RESILIENCE. The project coordinator is the CNIC in Madrid, Spain. Other partners are the European Society of Cardiology (ESC), France; IIS-Fundación Jiménez Díaz, Spain; Philips Healthcare, The Netherlands; Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, The Netherlands; Aarhus Universitetshospital, Denmark; Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Portugal; GLSMED Learning Health SA-Hospital da Luz, Portugal; Heinrich-Heine-Universität Düsseldorf, Germany; Centre Regional de Lutte Contre le Cancer Henri Becquerel Rouen, France; Centro de Investigacion Biomedica En Red (CIBER), Spain; and Philips Iberica, Spain. Other centres participate as third parties for trial execution and are listed in online supplementary Appendix S1.

Lymphoma Coalition Europe (LCE) collaborates with the project.

Discussion

The introduction of anthracyclines, incorporated into various immunochemotherapy regimens, was a significant breakthrough in the prognosis of patients with cancer. Unfortunately, however, cancer survivors often develop AC, limiting their QoL. A third of patients receiving high-dose anthracyclines develop some degree of AC, and irreversible injury leading to chronic HF⁴ occurs in a smaller proportion (approximately 6% of cancer survivors).⁵ Given the large numbers of patients receiving anthracyclines every year in Europe, these proportions translate into a vast population of cancer survivors living with AC (an estimated >1 million EU citizens). This problem is expected to intensify as a consequence of increasing cancer incidence and survival rates. For cancer survivors, the trade-off between cancer and chronic HF is an enormous psychological burden, and the growing incidence of chronic HF also has devastating consequences for healthcare systems.

Randomized clinical trials testing diverse cardioprotective AC prevention strategies have produced contrasting results. One of the most attractive pharmacological strategies is to encapsulate anthracyclines in pegylated or non-pegylated liposomes; however, this approach is not approved for AC prevention in Europe.^{21,22} Another pharmacological strategy involves the use of dexrazoxane, an iron chelator that blocks the formation of anthracycline–iron complexes and thus decreases superoxide

radical generation. Dexrazoxane also induces changes in the conformation of topoisomerase 2b. However, dexrazoxane does not show a consistent cardioprotective effect against AC, and there has been no definitive trial.²³

Several, mostly small, trials have tested the AC-protective potential of drugs widely used in cardiovascular medicine. Among the most frequently tested therapies are beta-blockers,^{24–26} renin–angiotensin–aldosterone system inhibitors,^{27–29} and statins,^{30–34} albeit results are not conclusive. In RESILIENCE, randomization is stratified for baseline LVEF, sex and enrolling centre. We decided not to stratify for established cardiovascular therapies with possible cardioprotective effects due to the intermediate size of the trial. Still, all baseline (and follow-up) medications will be collected and we will be able to account for their use.

The most encouraging results so far have come from the STOP-CA trial,³⁴ which compared the cardioprotective effect of 40 mg/day atorvastatin versus placebo in 300 lymphoma patients receiving moderate-to-high dose anthracyclines. The incidence of cardiotoxic events (a pre-specified decline in LV systolic function on CMR) was significantly lower in patients allocated to the statin treatment arm. In contrast, another recent (smaller) CMR-based trial in patients with diverse cancers found no cardioprotective effect of 40 mg/day atorvastatin.³³ Like the RESILIENCE trial, the STOP-CA trial³⁴ enrolled patients with lymphoma who were scheduled for moderate-to-high dose anthracycline chemotherapy (and thus had an elevated risk for AC) and used CMR as the main outcome measure. The RESILIENCE population is expected to have an even higher AC risk because aside from moderate-to-high anthracycline dose participants must have ≥ 1 additional AC risk factor (see inclusion criteria in Table 1). Risk factors that predispose patients to AC include a history of ischaemic heart disease, previous exposure to anticancer treatments, and hypertension. The selected risk factors in RESILIENCE are aligned with the latest ESC cardio-oncology guidelines (detailed information on AC risk factors is presented in Table 4 of these guidelines).⁴ One possible reason why most previous trials of AC prevention strategies have failed is that they enrolled all comers rather than focusing on patients with risk factors for this adverse event.³⁵ The anticipated risk-factor profile in RESILIENCE predicts a very high risk for AC in this population, thus maximizing the potential benefits of an effective cardioprotective intervention. Despite elevated cardiac biomarkers at baseline is considered a moderate risk factor for AC,⁴ we decided not to include this among our criteria. Two main reasons drove us to this decision: (i) elevated BNP has been proposed to be associated with cancer-related inflammatory status and not necessarily with a cardiac condition^{36,37}; and (ii) for the specific case of lymphoma, N-terminal proBNP has been shown to be a cancer-related prognostic marker.³⁸ For the same reasons, cardiac biomarker dynamics between groups are not among the pre-specified endpoints. However, the same day of each CMR study, cardiac injury biomarkers (hsTn) and BNP will be obtained per protocol for further post-hoc analyses.

The cardioprotective intervention to be tested in the RESILIENCE trial is RIC. The selection of this treatment is based on consistent pre-clinical experimental results.⁸ In a pig

model of AC that results in severe LV systolic dysfunction after five cycles of doxorubicin (every second week), the application of RIC before each doxorubicin dose resulted in significant LVEF preservation.⁸ In the same pre-clinical trial, transmission electron microscopy indicated that RIC protects against AC by preserving mitochondrial structure and function,⁸ a suitable mechanism of action given the central role of mitochondrial damage in AC.³⁹ Another possible benefit of this mechanism of action of RIC is that it differs from that of other potential cardioprotective strategies such as statins, and is thus likely to be non-redundant with those approaches.³⁴

The effects of RIC in preventing AC have been reported in two very recent small clinical trials.^{40,41} In the ERIC-ONC trial,⁴⁰ 55 adult patients (mean age 49 years) receiving anthracyclines were randomly assigned to either RIC or sham before each chemotherapy cycle. The primary outcome, circulating levels of cardiac troponin (cTn), did not differ between groups. The trial was underpowered and prematurely halted due to the COVID-19 pandemic. Notably, at 3 months, there were minimal changes in echocardiography-determined LVEF and LV GLS in either group, suggesting that the population had a very low AC risk. The second trial investigated the effects of RIC in a paediatric population of 68 patients (mean age 11 years) with diverse cancers.⁴¹ The primary outcome was again circulating cTn and again did not differ between groups. In this trial, the mean cumulative anthracycline dose was low, reflecting the low AC risk of this population. AC prevalence was very low in both trials, and neither trial showed evidence of deteriorated LV function, indicating that anthracyclines did not induce significant cardiomyopathy in these populations and thus limiting the ability of these trials to demonstrate a cardioprotective effect of any intervention. Unlike these trials, the RESILIENCE population will have a high AC risk, increasing the chance of documenting a protective effect of RIC in a more vulnerable population. Another important difference is that the primary outcome in RESILIENCE is directly assessed myocardial function and composition by CMR, not circulating cTn. The release of cTn to the bloodstream is in most instances secondary to the destruction of cardiomyocytes, and thus does not inform on the frequent association of AC with dysfunctional but viable cardiomyocytes. These dysfunctional cardiomyocytes result in functional ventricular deterioration, but not necessarily in significant troponin release to the bloodstream.

One of the key secondary outcomes in RESILIENCE is the incidence of AC events, pre-defined as a binary outcome according to the drop in LVEF. A similar approach was taken in the STOP-CA trial, in which the incidence of AC events was the primary outcome (pre-defined as an absolute decline in LVEF $\geq 10\%$ from pre- to post-chemotherapy to a final value of $< 55\%$).³⁴ The AC event criteria in RESILIENCE differ slightly from those in STOP-CA, with an AC event defined as either an absolute drop in LVEF of 10% regardless of the final value or an absolute drop of 5–10% to an LVEF $< 50\%$. Establishing endpoints based on cardiac function thresholds and dichotomizing patients into categories of absence or presence of cardiotoxicity aligns with the stratification of AC proposed by the ESC cardio-oncology clinical practice guidelines.⁴

Cardiac magnetic resonance is established as the best modality for the evaluation of cardiac anatomy, function, and tissue composition in a single session. CMR can also be used to evaluate the status of the microcirculation, another compartment affected by AC.⁴² CMR is therefore recommended in consensus documents as the main outcome measure for phase 2 trials.^{13,43} In the RESILIENCE trial, 608 patients at high-risk for AC will undergo three serial scans with a comprehensive state-of-the-art CMR protocol over a 6-month period. The selected CMR time points are based on previous AC studies. Most incidences of anthracycline chemotherapy-related cardiotoxicity manifest within the first year.⁴⁴

The CMR protocol in RESILIENCE includes evaluation of anatomy and function, tissue characterization, LV strain, and analysis of extracellular space (Figure 2). This large-scale evaluation in a controlled randomized trial, including > 1500 CMR scans, represents a pioneering effort to comprehensively assess cancer patients undergoing chemotherapy. RESILIENCE will provide robust scientific evidence supporting the utility of CMR for the management of patients with cancer and at high-risk for AC, contributing to the implementation of personalized approaches. A large subgroup of the RESILIENCE participants will additionally be examined using new CMR sequences not yet available in daily practice: the ESSOS 3D single breath-hold cine imaging sequence,¹⁴ quantitative perfusion,¹⁹ and fast-SENC.^{20,45}

The European Commission-funded RESILIENCE trial is a patient-centred endeavour that will contribute to improved care of cancer patients at risk for AC. The trial has been designed to address several key challenges within a single population of ~ 600 study participants: testing the utility of RIC as an innovative cardioprotective intervention, improving early AC diagnostic algorithms, and validating novel CMR sequences aimed at improving the comfort of these vulnerable patients. By using a highly comprehensive CMR protocol, RESILIENCE will not only employ the most accurate method for determining the primary endpoint, but also enable comparison of T2 relaxation time prolongation, LV strain, and cardiac injury markers as early markers of AC. The programmed testing of the ultrafast CMR cine sequence moreover has the potential to establish a new gold standard for the rapid assessment of cardiac anatomy and function in a single breath-hold CMR exam, an advance that would increase accessibility of this modality to vulnerable populations, such as elderly, paediatric, and cancer patients.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Funding

The RESILIENCE trial is funded by the European Commission (H2020-HEALTH, grant number 945118).

Conflict of interest: J.S.G. and J.S. are Philips employee. All other authors have nothing to disclose.

References

- Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. *Lancet* 2021;**398**:1518–1527. [https://doi.org/10.1016/S0140-6736\(20\)32207-8](https://doi.org/10.1016/S0140-6736(20)32207-8)
- Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: A systematic review. *Blood Adv* 2021;**5**:2426–2437. <https://doi.org/10.1182/bloodadvances.2021004665>
- Bhatia S. Genetics of Anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol* 2020;**2**:539–552. <https://doi.org/10.1016/j.jacc.2020.09.006>
- Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J* 2022;**43**:4229–4361. <https://doi.org/10.1093/eurheartj/ehac244>
- López-Sendón J, Álvarez-Ortega C, Zamora Auñón P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anti-cancer therapy-induced cardiotoxicity: The CARDIOTOX registry. *Eur Heart J* 2020;**41**:1720–1729. <https://doi.org/10.1093/eurheartj/ehaa006>
- Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, et al.; International Cardio-Oncology Society. priorities in cardio-oncology basic and translational science: GCOS 2023 symposium proceedings: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol* 2023;**5**:715–731. <https://doi.org/10.1016/j.jacc.2023.08.003>
- Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. *J Am Coll Cardiol* 2015;**65**:177–195. <https://doi.org/10.1016/j.jacc.2014.10.031>
- Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, et al. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. *Cardiovasc Res* 2021;**117**:1132–1143. <https://doi.org/10.1093/cvr/cvaa181>
- Bromage DI, Pickard JM, Rossello X, Ziff OJ, Burke N, Yellon DM, et al. Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: A systematic review and meta-analysis. *Cardiovasc Res* 2017;**113**:288–297. <https://doi.org/10.1093/cvr/cvw219>
- Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, et al.; CONDI-2/ERIC-PPCI Investigators. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): A single-blind randomised controlled trial. *Lancet* 2019;**394**:1415–1424. [https://doi.org/10.1016/S0140-6736\(19\)32039-2](https://doi.org/10.1016/S0140-6736(19)32039-2)
- Galán-Arriola C, Lobo M, Vilchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. *J Am Coll Cardiol* 2019;**73**:779–791. <https://doi.org/10.1016/j.jacc.2018.11.046>
- Martin-García A, Diaz-Pelaez E, Lopez-Corral L, Sanchez-Pablo C, Macias de Plasencia G, Galan-Arriola C, et al. T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer. *JACC Cardiovasc Imaging* 2020;**13**:1630–1632. <https://doi.org/10.1016/j.jcmg.2020.01.017>
- Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. *J Am Coll Cardiol* 2019;**74**:238–256. <https://doi.org/10.1016/j.jacc.2019.05.024>
- Gómez-Talavera S, Fernandez-Jimenez R, Fuster V, Nothnagel ND, Kouwenhoven M, Clemence M, et al. Clinical validation of a 3-dimensional ultrafast cardiac magnetic resonance protocol including single breath-hold 3-dimensional sequences. *JACC Cardiovasc Imaging* 2021;**14**:1742–1754. <https://doi.org/10.1016/j.jcmg.2021.02.031>
- Blauenfeldt RA, Hjort N, Valentin JB, Homburg AM, Modrau B, Sandal BF, et al. Remote ischemic conditioning for acute stroke: The RESIST randomized clinical trial. *JAMA* 2023;**330**:1236–1246. <https://doi.org/10.1001/jama.2023.16893>
- Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: A single-centre randomised, double-blind, controlled trial. *Lancet* 2013;**382**:597–604. [https://doi.org/10.1016/S0140-6736\(13\)61450-6](https://doi.org/10.1016/S0140-6736(13)61450-6)
- Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, et al.; ERICCA Trial Investigators. Remote ischemic preconditioning and outcomes of cardiac surgery. *N Engl J Med* 2015;**373**:1408–1417. <https://doi.org/10.1056/NEJMoa1413534>
- Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2014;**15**:1063–1093. <https://doi.org/10.1093/ehjci/jeu192>
- Sanchez-Gonzalez J, Fernandez-Jimenez R, Nothnagel ND, Lopez-Martin G, Fuster V, Ibanez B. Optimization of dual-saturation single bolus acquisition for quantitative cardiac perfusion and myocardial blood flow maps. *J Cardiovasc Magn Reson* 2015;**17**:21. <https://doi.org/10.1186/s12968-015-0116-2>
- Bucius P, Erley J, Tanacil R, Zieschang V, Giusca S, Korosoglou G, et al. Comparison of feature tracking, fast-SENC, and myocardial tagging for global and segmental left ventricular strain. *ESC Heart Fail* 2020;**7**:523–532. <https://doi.org/10.1002/ehf2.12576>
- Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. *BMC Cancer* 2010;**10**:337. <https://doi.org/10.1186/1471-2407-10-337>
- O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol* 2004;**15**:440–449. <https://doi.org/10.1093/annonc/mdh097>
- Zheng H, Zhan H. Preventing anthracycline-associated heart failure: What is the role of dexrazoxane? *JACC CardioOncol* 2024;**6**:318–321. <https://doi.org/10.1016/j.jacc.2024.01.004>
- Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). *J Am Coll Cardiol* 2013;**61**:2355–2362. <https://doi.org/10.1016/j.jacc.2013.02.072>
- Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. *J Am Coll Cardiol* 2018;**71**:2281–2290. <https://doi.org/10.1016/j.jacc.2018.02.049>
- Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity – a systematic review and meta-analysis of carvedilol. *Heart Fail Rev* 2019;**24**:325–333. <https://doi.org/10.1007/s10741-018-9755-3>
- Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail* 2015;**17**:81–89. <https://doi.org/10.1002/ehf.196>
- Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J* 2016;**37**:1671–1680. <https://doi.org/10.1093/eurheartj/ehw022>
- Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al.; ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur J Cancer* 2018;**94**:126–137. <https://doi.org/10.1016/j.ejca.2018.02.005>
- Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. *J Am Coll Cardiol* 2011;**58**:988–989. <https://doi.org/10.1016/j.jacc.2011.05.025>
- Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: A randomized, single-blind, placebo-controlled trial. *J Cardiovasc Pharmacol Ther* 2019;**24**:233–241. <https://doi.org/10.1177/1074248418821721>
- Hundley WG, D'Agostino R, Crotts T, Craver K, Hackney MH, Jordan JH, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. *NEJM Evid* 2022;**1**:evidoa2200097. <https://doi.org/10.1056/EVIDoa2200097>
- Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. *Eur Heart J Cardiovasc Pharmacother* 2023;**9**:515–525. <https://doi.org/10.1093/ehjcvp/pvad031>
- Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobní ZD, Gilman HK, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: The STOP-CA randomized clinical trial. *JAMA* 2023;**330**:528–536. <https://doi.org/10.1001/jama.2023.11887>

35. Ibanez B, Gomes-Silva M. Remote ischemic conditioning for anthracycline cardiotoxicity: The need to protect the most vulnerable. *JACC CardioOncol* 2023;5:356–359. <https://doi.org/10.1016/j.jacc.2023.05.002>
36. Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K, et al. Plasma brain natriuretic peptide levels are elevated in patients with cancer. *PLoS One* 2017;12:e0178607. <https://doi.org/10.1371/journal.pone.0178607>
37. Tuñón J, Pello A, Aceña Á, Ramos-Cillán S, Martínez-Milla J, González-Lorenzo Ó, et al. N-terminal pro-brain natriuretic peptide plasma levels are associated with intermediate-term follow-up cancer in coronary patients. *J Clin Med* 2021;10:4042. <https://doi.org/10.3390/jcm10184042>
38. Gimeno E, Gómez M, González JR, Comín J, Alvarez-Larrán A, Sánchez-González B, et al. NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. *Leuk Res* 2011;35:715–720. <https://doi.org/10.1016/j.leukres.2011.01.018>
39. Heusch G, Andreadou I, Bell R, Bertero E, Botker HE, Davidson SM, et al. Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. *Redox Biol* 2023;67:102894. <https://doi.org/10.1016/j.redox.2023.102894>
40. Mallouppas M, Chung R, Ghosh AK, Macklin A, Yellon DM, Walker JM. Anthracyclines and biomarkers of myocardial injury: The effect of remote ischemic conditioning. *JACC CardioOncol* 2023;5:343–355. <https://doi.org/10.1016/j.jacc.2023.03.008>
41. Cheung YF, Li VW, So EK, Cheng FW, Yau JP, Chiu SY, et al. Remote ischemic conditioning in pediatric cancer patients receiving anthracycline chemotherapy: A sham-controlled single-blind randomized trial. *JACC CardioOncol* 2023;5:332–342. <https://doi.org/10.1016/j.jacc.2022.11.020>
42. Galán-Arriola C, Vilchez-Tschischke JP, Lobo M, López GJ, de Molina-Iracheta A, Pérez-Martínez C, et al. Coronary microcirculation damage in anthracycline cardiotoxicity. *Cardiovasc Res* 2022;118:531–541. <https://doi.org/10.1093/cvr/cvab053>
43. von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology: A comprehensive summary and update. *J Cardiovasc Magn Reson* 2023;25:42. <https://doi.org/10.1186/s12968-023-00950-z>
44. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation* 2015;131:1981–1988. <https://doi.org/10.1161/CIRCULATIONAHA.114.013777>
45. Giusca S, Korosoglou G, Montenbruck M, Geršak B, Schwarz AK, Esch S, et al. Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: A longitudinal cardiac resonance imaging study during 2 years of follow-up. *Circ Cardiovasc Imaging* 2021;14:e012459. <https://doi.org/10.1161/CIRCIMAGING.121.012459>

APPENDIX 1

Participating centers and investigators

Center	Principal Investigator(s)	Investigators in the research team
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid SPAIN	Borja Ibanez	Noemi Escalera Antonio Quesada Navidad Andrea Moreno-Arciniegas Irene Sempere Rodríguez Jesús Molina Carretero Ignacio Polo Vaquero Ángel Franch Manchón Antonio Ureña Linde Tamara Fernández Delgado Samuel Pérez Fernández Fernando Benito Valtueña Manuel Desco Menéndez Xavier Rosselló
Fundación Jiménez Díaz, Madrid, SPAIN	Raúl Córdoba	Alberto López García Sandra Gómez-Talavera María López Álvarez Alba María Vega Viyuela Laura Pardo Gambarte Daniel Morillo Giles María de los Ángeles Pérez Saenz Ester Macía Palafox
University of Düsseldorf, GERMANY	Malte Kelm	Amin Polzin Saskia Pietrucha Fabian Voss Sascha Dietrich Ulrich Germing Chiara Berste
Aarhus University Hospital, DENMARK	Francesco D'Amore	Peter Martin Hjørnet Kamper Sanne Nagstrup Kjær Won Yong Kim Katrine Frikke Andersen
Instituto Português de Oncologia Francisco Gentil, Lisbon, PORTUGAL	Maria Gomes da Silva	Maria do Céu Trindade Diana Viegas Vanessa Beijamini
Philips Healthcare, THE NETHERLANDS	Jouke Smink Javier	Ece Ercan
Philips Healthcare Iberia, SPAIN	Javier Sánchez-González	Álvaro Navarro Guzmán
European Society of Cardiology, Nice FRANCE.	Teresa López-Fernández Riccardo Asteggiano	Elsa Pacella
GLSMED / Hospital da Luz, Lisbon, PORTUGAL	António Ferreira	Fernando Gonçalves
Centro de Investigación Biomédica en Red (CIBER), Madrid, SPAIN	Pedro L Sánchez	Alberto San Román Ana Martín
Centre Henri Becquerel, Department of Hematology and INSERM U1245, Rouen, FRANCE	Vincent Camus	Hervé Tilly Fabrice Jardin Aspasia Stamatoullas Juliette Penichoux Nathalie Contentin Alexandra Zduniak Pierre Lebreton Mustafa Alani Stephane Lepretre

		Pascal Lenain Florian Bouclet Helene Lanic Anne-Lise Menard Emilie Lemasle Sydney Dubois Oana Brehar Doriane Richard Ridha Belilita
Amsterdam University Medical Center (AUMC), THE NETHERLANDS	Maria José Kersten,	Aart J Nederveen Esra Eyiis Koen de Heer
Hospital Ramón y Cajal. Irycis. Madrid. Universidad de Alcalá de Henares. SPAIN	Javier López-Jiménez	Esther Agea
Hospital Clínico Universitario de Valladolid, SPAIN	María Jesús Peñarrubia	Carlos Baladrón Ana Revilla-Orodea
Hospital Clínico de Salamanca, SPAIN	Alejandro Martín	Candelas Perez del Villar Moro. Norma Carmen Gutiérrez Gutiérrez Ramón García-Sanz Leticia Vicente Pachó Clara Sanchez Pablo
Hospital Clínico San Carlos, Madrid, SPAIN	Celina Benavente	Rosa María Tarradas Begoña Navas Elorza Gonzalo del Campo Balguerías Estefanía Bolaños Calderón Javier Cucharero Martín
Hospital La Paz, IdiPAZ research Institute, Madrid, SPAIN	Irene Sánchez Vadillo	Raquel Gil Paloma Pastor
Hospital Gregorio Marañón Madrid, SPAIN	Mariana Bastos	Mireia Bañuls García
Hospital Doce de Octubre Madrid, SPAIN	Ana Jiménez Ubieto,	Alba Gutiérrez de la Peña
Hospital Puerta de Hierro Majadahonda, SPAIN	María Belén Navarro	José Antonio García Vela
Institut Català d'Oncologia (ICO), Barcelona, SPAIN	Eva González Barca	Gabriela De Aquino Palma
Hospital Virgen de las Nieves, Granada SPAIN	José Manuel Puerta,	Sandra Gómez Lopera Genaro López Milena
Hospital Virgen del Rocío, Sevilla, SPAIN	Guillermo Rodríguez	Mª José Rivero María Del Pilar Serrano Gotarredona
Centro Médico Teknon, Barcelona, SPAIN	Antonio Berruezo	Daniel Viveros Alba Magliano Mercedes Iglesias Marina Huguet Pañella
Rouen University Hospital, Department of Radiology, Normandie University, UNIROUEN, INSERM U1096, Rouen, FRANCE	Jean-Nicolas Dacher	Sébastien Normant
Hospital Universitario Ruber Juan Bravo, Madrid, SPAIN	Arancha Alonso	Alejandra Segado de la Torre Mariana Tercero Mora
Hospital Universitario Infanta Leonor, Madrid, SPAIN	Jose Angel Hernández Rivas	María Stefania Infante Isabel González Gascón y Marín Maria Angeles Foncillas García Carolina Muñoz Novas Raquel Fernandez Ordoño Adrian Porcel Almendral
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, SPAIN	Julio García Suarez	Ana Puchol Crespo Elena Flores Ballester Elena Magro Mazo Isabel Gutierrez Jomarron

		Juan Jose Gil Fdez Marta Callejas Chavarria Patricia Garcia Ramirez Yolanda Martin Guerrero Paola Villafuerte Gutierrez Montserrat Lopez Rubio
Hospital Jaques Monod, El Havre, FRANCE	Pierre Lebreton	Alexandra Zduniak Angélique Picard